PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8928093

A rapid genotype assay for Pla haplotypes.

G M Pfaffenbach·J A Bussel·P Rubinstein
View original source ↗Export metadata ↓

Abstract

The method described here results in simple visual analysis of 1, 2, or 3 ethidium bromide-stained bands corresponding to the PlA1, PlA2 or PlA1/A2 phenotypes, respectively. The amplification primers, designed to yield a 711bp product which encompasses exon 2 and substantial intronic sequence both 5' and 3' of the exon enable exquisite resolution of the restriction enzyme digestion products which define the alleles. In addition to prediction of fetal risk of neonatal alloimmune thrombocytopenia using this method, an ethnically heterogeneous pool of platelet donors was screened for the platelet antigen PlA (HPA-1) and gave unequivocal results which should be useful for platelet matching.

Explore related subjects

Antigens, Human PlateletBase SequenceColoring AgentsDNAEthidiumFemaleGenome, HumanGenotypeHaplotypesHumansMaleMolecular Sequence DataPolymerase Chain ReactionPredictive Value of TestsPrenatal DiagnosisTemplates, GeneticThrombocytopeniaTime FactorsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G M Pfaffenbach, J A Bussel, P Rubinstein. 1996-02-01. A rapid genotype assay for Pla haplotypes.. https://doi.org/10.1016/0049-3848(96)00007-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Maternal human platelet antigen-1a antibody level correlates with the platelet count in the newborns: a retrospective study.

BACKGROUND: Maternal plasma and/or serum levels of anti-HPA-1a at delivery were compared to neonatal platelet (PLT) counts. STUDY DESIGN AND METHODS: Samples from HPA-1bb women who gave birth to children with thrombocytopenia or had anamnestic information about a previous child with neonatal alloimmune thrombocytopenia (NAIT) were collected at delivery. A modified monoclonal antibody immobilization of PLT antigen method was used for quantification of anti-HPA-1a. RESULTS: The anti-HPA-1a level in women with severely thrombocytopenic children was higher than the corresponding level in mothers of children born with moderate thrombocytopenia or normal PLT counts. CONCLUSION: Our data show a significant correlation between maternal anti-HPA-1a level and the neonatal PLT count and indicate strongly that this may be a reliable predictive measure for NAIT. Suitable test systems for quantitative measurements of anti-HPA-1a must be developed and evaluated for this particular purpose.

Antigens, Human Platelet↗
PubMed2006

Foetal and neonatal alloimmune thrombocytopaenia.

Foetal/neonatal alloimmune thrombocytopaenia (NAIT) results from maternal alloimmunisation against foetal platelet antigens inherited from the father and different from those present in the mother, and usually presents as a severe isolated thrombocytopaenia in otherwise healthy newborns. The incidence has been estimated at 1/800 to 1/1000 live births. NAIT has been considered to be the platelet counterpart of Rh Haemolytic Disease of the Newborn (RHD). Unlike RHD, NAIT can occur during a first pregnancy. The spectrum of the disease may range from sub-clinical moderate thrombocytopaenia to life-threatening bleeding in the neonatal period. Mildly affected infants may be asymptomatic. In those with severe thrombocytopaenia, the most common presentations are petechiae, purpura or cephalohaematoma at birth, associated with major risk of intracranial haemorrhage (up to 20% of reported cases), which leads to death or neurological sequelae. Alloimmune thrombocytopaenia is more often unexpected and is usually diagnosed after birth. Once suspected, the diagnosis is confirmed by demonstration of maternal antiplatelet alloantibodies directed against a paternal antigen inherited by the foetus/neonate. Post-natal management involves transfusion of platelets devoid of this antigen, and should not be delayed by biological confirmation of the diagnosis (once the diagnosis is suspected), especially in case of severe thrombocytopaenia. Prompt diagnosis and treatment are essential to reduce the chances of death and disability due to haemorrhage. Due to the high rate of recurrence and increased severity of the foetal thrombocytopaenia in successive pregnancies, antenatal therapy should be offered. However, management of high-risk pregnancies is still a matter of discussion.

Antigens, Human Platelet↗
PubMed2006

Alloimmune thrombocytopenia: state of the art 2006.

In alloimmune thrombocytopenia maternal immunoglobulin G anti-platelet alloantibodies cross the placenta and cause fetal thrombocytopenia. The diagnosis requires laboratory demonstration of incompatibility between a maternal and paternal platelet alloantigen, and detection of maternal antibody to the discordant paternal alloantigen. This disorder should be treated in utero because of its propensity to cause fetal intracranial bleeding. Administration of intravenous immunoglobulin 1 gm/kg/wk to the mother is successful in substantially raising the platelet count in many fetuses, but this is most successful if the count is >20,000/mL3 at the time that the therapy is initiated. The addition of prednisone administered daily to the mother and/or increasing the dose of intravenous immunoglobulin has a therapeutic benefit in cases that have failed to respond to initial therapy with intravenous immunoglobulin alone. The only reliable noninvasive indicator of the potential for severe fetal thrombocytopenia is a history of an antenatal intracranial hemorrhage in a prior affected sibling. Because fetal blood sampling to determine the fetal platelet count may be associated with significant fetal morbidity, attempts are being made to derive a rational, non-invasive, stratified approach to patient-specific therapy of this disorder in affected pregnancies.

Antigens, Human Platelet↗